1H,3h-苯并[de]异喹啉-2-胺 | 42773-02-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1H,3h-苯并[de]异喹啉-2-胺
• 中文别名: 1H,3H-苯并[DE]异喹啉-2-氨基
• 英文名称: 1H,3H-benzo[de]isoquinolin-2-ylamine
• 英文别名: 2-Amino-2,3-dihydro-1H-benzoisochinolin；1H-Benzo[DE]isoquinolin-2(3H)-amine；1,3-dihydrobenzo[de]isoquinolin-2-amine
• CAS: 42773-02-4
• 化学式: C₁₂H₁₂N₂
• mdl: MFCD04114924
• 分子量: 184.241
• InChiKey: JSKSZCLHCISZEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1H,3h-苯并[de]异喹啉-2-胺 生成 1-(1,3-dihydrobenzo[de]isoquinolin-2-yl)-3-methylthiourea
  参考文献：
  名称：

  COHNEN, E.;ARMAH, B.

  摘要：

  DOI：

文献信息

• Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1743888A1

  公开（公告）日：2007-01-17

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及取代吡唑啉化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• Active substance combination for the treatment of diabetes
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946778A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, used to treat diabetes, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，用于治疗糖尿病，包括该活性物质组合的药物、包括该活性物质组合的制药配方以及利用该活性物质组合制造药物的用途。
• Substituted pyrazoline for preventing weight gain
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946777A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，该药物以体重增加作为副作用而知名，包括所述活性物质组合的药物、包括所述活性物质组合的药物制剂、以及利用所述活性物质组合制造药物。
• Compounds having unique CB1 receptor binding selectivity and methods for their production and use
  申请人：Research Triangle Institute

  公开号：US20030199536A1

  公开（公告）日：2003-10-23

  Compounds are provided that are amide analogs of SR141716A having unique CB1 receptor selectivity and providing WIN sparing binding characteristics, pharmaceutical compositions containing the compounds and their use in a method of treatment of CB1 receptor related disorders, such as obesity, schizophrenia, memory dysfunction and marijuana abuse.

  提供了一些化合物，它们是SR141716A的酰胺类似物，具有独特的CB1受体选择性和WIN保留结合特性，制备了含有这些化合物的药物组合物，并将其用于治疗与CB1受体相关的疾病，如肥胖症、精神分裂症、记忆功能障碍和大麻滥用等方法。
• 4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments
  申请人：TORRENS Antoni

  公开号：US20070073056A1

  公开（公告）日：2007-03-29

  The present invention relates to 4-substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及4-取代吡唑啉化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。